| First Author | Drost R | Year | 2014 |
| Journal | Oncogene | Volume | 33 |
| Issue | 29 | Pages | 3753-63 |
| PubMed ID | 23955079 | Mgi Jnum | J:212611 |
| Mgi Id | MGI:5581880 | Doi | 10.1038/onc.2013.329 |
| Citation | Drost R, et al. (2014) Opportunities and hurdles in the treatment of BRCA1-related breast cancer. Oncogene 33(29):3753-63 |
| abstractText | BRCA1 functions as a classical tumor suppressor in breast and ovarian cancer. While the role of BRCA1 in homology-directed repair of DNA double-strand breaks contributes to its tumor suppressive activity, it also renders BRCA1-deficient cells highly sensitive to DNA-damaging agents. Although BRCA1 deficiency is therefore considered to be an attractive therapeutic target, re-activation of BRCA1 by secondary mutations has been shown to cause therapy resistance. In this review, we will assess the role of BRCA1 in both hereditary and sporadic breast cancer and discuss how different functionalities of the BRCA1 protein can contribute to its tumor suppressor function. In addition, we will discuss how this knowledge on BRCA1 function can help to overcome the hurdles encountered in the clinic and improve current treatment strategies for patients with BRCA1-related breast cancer. |
